Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 13c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.64), $0.13 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $97.9 thousand, versus $30.66 thousand reported last year.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Fiserv (FI) Tops Q1 EPS by 9c; Boosts outlook
• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts